arrow
M

Minkyu Jung

The Catholic University of Korea
H指数:32
被引数:3,535

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Real-World Outcomes and Biomarker Analysis Based on Routine Clinical, Laboratory, and Pathologic Parameters in Metastatic or Unresectable Esophageal Cancer Treated with First-Line Anti-PD-1 Plus Fluoropyrimidine and Platinum

基于常规临床、实验室和病理参数的转移性或不可切除食管癌患者接受一线抗PD-1联合氟嘧啶和铂类药物治疗的真实世界结局与生物标志物分析

2025-09-280
OAAI
Real-world outcomes of third-line immune checkpoint inhibitors versus irinotecan-based chemotherapy in patients with advanced gastric cancer: a Korean, multicenter study (KCSG ST22-06)

在晚期胃癌患者中,三线免疫检查点抑制剂与基于伊立替康的化疗的真实世界结果: 韩国多中心研究 (KCSG ST22-06)

2024-02-232
OAAI
Prior antibiotic administration disrupts anti-PD-1 responses in advanced gastric cancer by altering the gut microbiome and systemic immune response

先前使用抗生素通过改变肠道微生物组和全身免疫反应来破坏晚期胃癌的anti-PD-1反应

2023-11-015
OAAI
Second-line chemoimmunotherapy with nivolumab and paclitaxel in immune-related biomarker-enriched advanced gastric cancer: a multicenter phase Ib/II study

nivolumab和紫杉醇二线化学免疫治疗免疫相关生物标志物富集的晚期胃癌: 一项多中心Ib/II期研究

2023-10-315
PRE
Impact of Coronavirus Disease 2019 on Gastric Cancer Diagnosis and Stage: A Single-Institute Study in South Korea

冠状病毒疾病2019对胃癌诊断和分期的影响: 韩国的一项单研究所研究

2023-01-011
OAAI
Korean Practice Guidelines for Gastric Cancer 2022: An Evidence-based, Multidisciplinary Approach (vol 23, pg 3, 2023)
2023-01-012
OAAI
Korean Practice Guidelines for Gastric Cancer 2022: An Evidence-based, Multidisciplinary Approach

韩国胃癌2022实践指南: 基于证据的多学科方法

2023-01-01160
OAAI